Pharmacokinetics of oltipraz in mutant Nagase analbuminemic rats

Journal of Pharmaceutical Sciences

Volumn 95, Issue 5, 2006, Pages 998-1005

  Bae, Soo K ^a   Kang, Hee E ^a   Kang, Min K ^a   Kim, Jin W ^b   Kim, Taekrho ^b   Lee, Myung G ^a  

^a Seoul National University   (South Korea)

^b CJ Corporation   (South Korea)

Author keywords

CYP enzymes; CYP1A2; Metabolism; Mutant Nagase analbuminemic rats; Oltipraz; Pharmacokinetics; Protein binding

Indexed keywords

CYTOCHROME P450 1A1; CYTOCHROME P450 1A2; CYTOCHROME P450 1B1; CYTOCHROME P450 2B2; CYTOCHROME P450 2C11; CYTOCHROME P450 3A1; CYTOCHROME P450 3A2; OLTIPRAZ;

ANALBUMINEMIA; ANIMAL EXPERIMENT; ANIMAL MODEL; AREA UNDER THE CURVE; ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DOSE RESPONSE; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG CLEARANCE; DRUG HALF LIFE; DRUG METABOLISM; ENZYME BLOOD LEVEL; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; LIVER MICROSOME; MALE; NONHUMAN; PROTEIN BINDING; RAT;

EID: 33646542739     PISSN: 00223549     EISSN: 15206017     Source Type: Journal    
DOI: 10.1002/jps.20602     Document Type: Article

References (35)

1. Clapper M. 1998. Chemopreventive activity of oltipraz. Pharmacol Ther 78:17-27.
2. Kang KW, Kim YG, Cho MK, Bae SK, Kim CW, Lee MG, Kim SG. 2002. Oltipraz regenerates cirrhotic liver through CCAAT/enhancer binding protein-mediated stellate cell inactivation. FASEB J 16:1988-1990.
3. Bae SK, Lee SJ, Kim YH, Kim T, Lee MG. 2005. Effects of enzyme inducers and inhibitors on the pharmacokinetics of oltipraz in rats. J. Pharm Pharmacol 26:129-134.
4. Bae SK, Lee SJ, Kim YH, Kim JW, Kim SG, Lee MG. 2004. Effects of acute renal failure on the pharmacokinetics of oltipraz in rats. J Pharm Sci 93:2353-2363.
5. Bae SK, Yang SH, Kim JW, Kim T, Kwon JW, Lee MG. 2005. Effects of cysteine on the pharmacokinetics of oltipraz in rats with protein-calorie malnutrition. J Pharm Sci 94:1484-1493.
6. Bae SK, Lee SJ, Kim JW, Kim YH, Kim SG, Lee MG. 2005. Pharmacokinetics of oltipraz after intravenous and oral administration in rats with dehydration for 72 hours. Biopharm Drug Dispos 26:77-83.
7. Kim YC, Lee AK, Lee JH, Lee I, Lee DC, Kim SH, Kim SG, Lee MG. 2005. Pharmacokinetics of theophylline in diabetes mellitus rats: induction of CYP1A2 and CYP2E1 on 1,3-dimethyluric acid formation. Eur J Pharm Sci 26:114-123.
8. Kim EJ, Lee AK, Kim SH, Kim SG, Lee MG. 2003. Pharmacokinetics and pharmacodynamics of intravenous azosemide in mutant Nagase analbuminemic rats. Drug Metab Dispos 31:194-201.
9. Kim EJ, Suh OK, Lee MG. 2003. Pharmacokinetics of intravenous theophylline in mutant Nagase analbuminemic rats. Life Sci 72:1231-1245.
10. Lee SH, Lee MG. 1997. Effect of Phenobarbital, 3-methylcholanthrene and chloramphenicol pretreatment on the pharmacokinetics and pharmacodynamics of azosemide in rats. Biopharm Drug Dispos 18:371-386.
11. Teunissen MW, Brorens IO, Geerlings JM, Breimer DD. 1985. Dose-dependent elimination of theophylline in rats. Xenobiotica 15:156-171.
12. Bradford MM. 1976. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 72:248-254.
13. Bae SK, Bu SC, Kim EJ, Kim SH, Kim SG, Lee MG. 2001. Determination of a chemopreventive agent, oltipraz, in rat plasma and urine by high-performance liquid chromatography. Res Commun Mol Pathol Pharmacol 110:133-138.
14. Lineweaver H, Burk D. 1934. The determination of enzyme dissociation constants. J Am Chem Soc 56:658-666.
15. Shin JH, Choi KY, Kim YC, Lee MG. 2004. Dose-dependent pharmacokinetics of itraconazole after intravenous or oral administration to rats: intestinal first-pass effect. Antimicrob Agents Chemother 48:1756-1762.
16. Kim SH, Choi YM, Lee MG. 1993. Pharmacokinetics and pharmacodynamics of furosemide in protein-calorie malnutrition. J Pharmacokinet Biopharm 21:1-17.
17. Bae SK, Lee SJ, Kim YG, Kim SH, Kim JW, Kim T, Lee MG. 2005. Interspecies pharmacokinetic scaling of oltipraz in mice, rats, rabbits and dogs, and prediction of human pharmacokinetics. Biopharm Drug Dispos 26:99-115.
18. Bae SK, Kim JW, Kim YH, Kim YG, Kim SG, Lee MG. 2005. Hepatic and intestinal first-pass effects of oltipraz in rats. Biopharm Drug Dispos 26:129-134.
19. Bu SC, Kim EJ, Kim SH, Kim SG, Lee MG. 2001. Stability, blood partition and protein binding of an antifibrotic agent, oltipraz. Res Commun Mol Pathol Pharmacol 109:333-344.
20. Nagase S, Shimamune K, Shumiya S. 1980. Albumin-deficient rat mutant: an animal model for analbuminemia. Exp Anim 29:33-38.
21. Chiou WL, Nation RL, Peng GW, Huang SM. 1978. Improved micro-scale high-pressure liquid-chromatographic assay of gentamicin in plasma. Clin Chem 24:1846-1847.
22. Christensen RG, Malone W. 1992. Determination of oltipraz in serum by high-performance liquid chromatography with optical absorbance and mass spectrometric detection. J Chromatogr 584:207-212.
23. Chiou WL. 1978. Critical evaluation of potential error in pharmacokinetic studies using the linear trapezoidal rule method for the calculation of the area under the plasma level-time curve. J Pharmacokinet Biopharm 6:539-546.
24. Gibaldi M, Perrier D. 1982. Pharmacokinetics, 2nd edn. New York: Marcel-Dekker, Inc.
25. Chiou WL. 1980. New calculation method of mean total body clearance of drugs and its application to rational dosage regimens. J Pharm Sci 69:90-91.
26. Chiou WL. 1979. New calculation method for mean apparent drug volume of distribution and application to rational dosage regimen. J Pharm Sci 68:1067-1069.
27. Eatman FB, Colburn WA, Boxenbaum HG, Posmanter HN, Weinfeld RE, Ronfeld R, Weissman L, Moore JD, Gibaldi M, Kaplan SA. 1977. Pharmacokinetics of diazepam following multiple dose oral administration to healthy human subjects. J Pharmacokinet Biopharm 5:481-494.
28. Bieder A, Decouvelaere B, Gaillard C, Depaire H, Heusse D, Ledoux C, Lemar M, Leroy JP, Raynaud L, Snozzi C, Gregoire J. 1983. Comparison of the metabolism of oltipraz in the mouse, rat and monkey and in man. Distribution of the metabolites in each species. Arzneim-Forsch/Drug Res 33:1289-1297.
29. Kim EJ, Lee MG. 2001. Pharmacokinetics and pharmacodynamics of intravenous bumetanide in mutant Nagase analbuminemic rats: importance of globulin binding for the pharmacodynamics effects. Biopharm Drug Dispos 22:147-156.
30. Kim EJ, Lee MG. 2003. Pharmacokinetics and pharmacodynamics of intravenous torasemide in mutant Nagase analbuminemic rats. Biopharm Drug Dispos 24:27-35.
31. Takada K, Kawamura T, Inai M, Masuda S, Oka T, Yoshikawa Y, Shibata N, Yoshikawa H, Ike O, Wada H, Hitomi S. 1999. Pharmacokinetics of cisplatin in analbuminemic rats. Biopharm Drug Dispos 20:421-428.
32. Wilkinson GR, Shand DG. 1975. A physiological approach to hepatic drug clearance. Clin Pharmacol Ther 18:377-390.
33. Nagase S, Shimamune K, Shumiya S. 1979. Albumin deficient rat mutant. Science 205:590-591.
34. Xu BQ, Ishii M, Ding LR, Fischer NE, Inaba T. 2003. Interaction of serum proteins with CYP isoforms in human liver microsomes: inhibitory effects of human and bovine albumin, alpha-globulins, alpha-1-acid glycoproteins and gamma-globulins on CYP2C19 and CYP2D6. Life Sci 72:1953-1962.
35. Lee MG, Chiou WL. 1983. Evaluation of potential causes for the incomplete bioavailability of furosemide: gastric first-pass metabolism. J Pharmacokinet Biopharm 11:623-640.